Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 3/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL834995 | 0.82 | ACHE (0.43) | KDM1AHPGDSGPR119 | |
| SCHEMBL827042 | 0.82 | KDM1A (0.38) | KDM1AHPGDSGPR119JAK1JAK2 | |
| Ammonia Solution, Strong SCHEMBL27885711 | 0.80 | ACHE (0.42) | KDM1AHPGDSGPR119 | |
| SCHEMBL10271094 | 0.78 | KDM1A (0.36) | KDM1AHPGDSGPR119OPRM1OPRD1 | |
| SCHEMBL24914252 | 0.77 | HRH3 (0.38) | KDM1AHPGDSGPR119 | |
| SCHEMBL824189 | 0.77 | KDM1A (0.36) | KDM1AHPGDSGPR119OPRM1OPRD1 | |
| SCHEMBL17308225 | 0.75 | KDM1A (0.35) | KDM1AHPGDSGPR119 | |
| SCHEMBL445603 | 0.75 | KDM1A (0.39) | KDM1AHPGDSGPR119JAK1JAK2 | |
| SCHEMBL20160685 | 0.75 | KDM1A (0.39) | KDM1AHPGDSGPR119JAK1JAK2 | |
| SCHEMBL18024245 | 0.74 | ACHE (0.36) | KDM1AHPGDSGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | KDM1A 3640/4885HPGDS 200/4885GPR119 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.